Proton Pump Inhibitors Use in Patients With Psoriasis

Phase 4

Withdrawn

• Conditions: Psoriasis
• Interventions: Drug: esomeprazole; Drug: desonide

• Registration Number: NCT02624544
• Lead Sponsor: EMS

Brief Summary

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

Detailed Description

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

The study will assess the evolution of skin lesions in psoriasis patients using PPIs

Study Timeline

• Study First Submitted: 2015-11-13
• Study First Submitted QC: 2015-12-07
• Study First Posted: 2015-12-08
• Study Start: 2016-01
• Primary Completion: 2016-01
• Study Completion: 2016-12
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-03
• Last Update Posted: 2022-08-05

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Diagnostic of Psoriasis

Exclusion Criteria

• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	esomeprazole	Proton Pump Inhibitor esomeprazole 40 mg twice a day
Group B	desonide	desonide

Primary Outcome Measures

Name	Time	Method
Efficacy - Change from baseline in skin lesions at 5 months	Baseline - 5 months	Number of Participants With Treatment-Related Clinical Improvement of lesions Change From Baseline in skin lesions at 5 months